Abstract Details

Title Age and Orthostatic Hypotension in Parkinson Disease: Passive Tilt vs. Active Standing

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 145

Objective

Background BACKGROUND: Although both methods are used, it is not known whether active standing or HUT are better suited for the diagnosis of OH in patients with PD.

Design/Methods DESIGN/METHODS: We compared the frequency of OH (i.e., fall in 20/10 mmHg within 3 minutes) when assessed by HUT vs. active standing in 233 patients with PD. 116 patients (73 men and 43 women) underwent a 60 degree HUT and 117 patients (62 men and 53 women) underwent an active standing procedure. Blood pressure and heart rate were measured before and after 3 minutes in the upright position.

Results RESULTS: The prevalence of OH was 70% in those undergoing HUT and 41% in those undergoing active standing (p<0.001). However, patients undergoing HUT were significantly older (72.1 years vs. 61.2 years, p<0.001) and had higher systolic blood pressure while supine (151 vs. 134 mmHg, p<0.001). Prevalence of OH by age showed that the 40-50 yrs old group (n:15) had 20% prevalence of OH with HUT vs. 40% with active standing (NS); in the 50-60 yrs old group (n:38), 33% had OH with HUT vs. 47% with active standing (NS), in the 60-70 yr old group (n:67), 78% had OH with HUT vs. 43% with active standing (p<0.004), and in the 70-80 yrs old group (n:85), 60% had OH with HUT and 36% with active standing (p<0.04).

Conclusions CONCLUSIONS: In younger patients with PD active standing and HUT showed similar prevalence of OH. However, among PD patients 60 years and older the prevalence of OH was significantly higher with HUT than with active standing. These findings have practical implication for diagnosis and clinical management.

Authors/Disclosures
Horacio C. Kaufmann, MD, FAAN (NYU Langone Health - NYU Dysautonomia Center) PRESENTER	Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Theravance. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Kaufmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen Therapeutics. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioArctic. Dr. Kaufmann has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Spinger. The institution of Dr. Kaufmann has received research support from Biogen. The institution of Dr. Kaufmann has received research support from Vaxxinity. Dr. Kaufmann has received publishing royalties from a publication relating to health care.
	No disclosure on file
Juan Carlos Gomez Esteban, MD (Osakidetza)	Dr. Gomez Esteban has nothing to disclose.
	No disclosure on file
Koldo Berganzo Corrales, MD	No disclosure on file
Burk Jubelt, MD (SUNY Upstate Medical University)	No disclosure on file

��ɫ��

��ɫ��